19/09/2007,10541108III.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTASXY1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 02	LMEDLINE coverage updated
NEWS 3	JUL 02	SCISEARCH enhanced with complete author names
NEWS 4	JUL 02	CHEMCATS accession numbers revised
NEWS 5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 6	JUL 16	CAplus enhanced with French and German abstracts
NEWS 7	JUL 18	CA/CAplus patent coverage enhanced
NEWS 8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9	JUL 30	USGENE now available on STN
NEWS 10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 11	AUG 06	BEILSTEIN updated with new compounds
NEWS 12	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 13	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 14	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 15	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 16	AUG 27	USPATOLD now available on STN
NEWS 17	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 18	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 19	SEP 13	FORIS renamed to SOFIS
NEWS 20	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 21	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 22	SEP 17	CAplus coverage extended to include traditional medicine patents

NEWS EXPRESS 05 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 05 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:50:39 ON 19 SEP 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:50:50 ON 19 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1
DICTIONARY FILE UPDATES: 18 SEP 2007 HIGHEST RN 947490-11-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10541108III.str



chain nodes :
7 8 9 10 11 12 13 16 17 21 22 23 24 25 26 27 28
ring nodes :
1 2 3 4 5
chain bonds :
1-21 2-7 7-8 7-9 8-10 10-11 11-12 12-13 13-22 16-17 23-24 24-25 26-27
26-28
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 1-21 2-3 2-7 3-4 4-5 7-8 7-9 8-10 10-11 11-12 12-13 13-22
16-17 23-24 24-25 26-27 26-28

G1:S,CH2

G2:[*1],[*2],[*3]

G3:H,CN

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 16:CLASS 17:CLASS 21:CLASS 22:Atom 23:CLASS
24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS
Generic attributes :
22:
Type of Ring System : Polycyclic

L1 STRUCTURE UPLOADED

```
=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 10:51:09 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    25581 TO ITERATE

  7.8% PROCESSED     2000 ITERATIONS                                 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       502051 TO   521189
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 10:51:14 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   512103 TO ITERATE

 95.8% PROCESSED   490608 ITERATIONS                               63 ANSWERS

100.0% PROCESSED   512103 ITERATIONS                               63 ANSWERS
SEARCH TIME: 00.00.25

L3            63 SEA SSS FUL L1

=> file hcaplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               172.55     172.76

FILE 'HCAPLUS' ENTERED AT 10:51:50 ON 19 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 19 Sep 2007  VOL 147 ISS 13
FILE LAST UPDATED: 18 Sep 2007  (20070918/ED)
```

19/09/2007,10541108III.trn

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 6 L3

=> d ed abs ibib hitstr tot

L4 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 02 Nov 2006
GI



I

AB The invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitory compds. A-B-CO-D (A is a bicyclic or tricyclic ring system attached to B at carbon or nitrogen; B is a linking group such as an amino acid residue or fragment; D is a pyrrolidine or thiazolidine residue or derivative), including isomers and pharmaceutically-acceptable salts, for treatment of DPP-IV mediated diseases, in particular, type-2 diabetes. Thus, pyrrolidinecarbonitrile derivative I was prepared by reaction of 5-[(S)-2-aminopropyl]-10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-carboxamide with N-glyoxyloyl-L-prolinecarbonitrile (prepns. given) and showed Ki < 6 nM for inhibition of DPP-IV.

ACCESSION NUMBER: 2006:1147258 HCAPLUS
DOCUMENT NUMBER: 145:471864
TITLE: Preparation of multicyclic peptide derivatives as dipeptidyl peptidase-IV inhibitors
INVENTOR(S): Kroth, Heiko; Feuerstein, Tim; Richter, Frank; Boer, Jurgen; Essers, Michael; Nolte, Bert; Schneider, Matthias; Hochguertel, Matthias; Frickel, Fritz-Frieder; Taveras, Arthur
PATENT ASSIGNEE(S): Alantos Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 542pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006116157	A2	20061102	WO 2006-US15200	20060421
WO 2006116157	A9	20070301		
WO 2006116157	A3	20070419		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,

L4 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

AU 2006239929	A1	20061102	AU 2006-239929	20060421
US 2006270701	A1	20061130	US 2006-409481	20060421
PRIORITY APPLN. INFO.:			US 2005-674151P	P 20050422
			WO 2006-US15200	W 20060421

OTHER SOURCE(S): CASREACT 145:471864; MARPAT 145:471864
IT 913978-13-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of multicyclic peptide derivs. as dipeptidyl peptidase-IV inhibitors)
RN 913978-13-9 HCAPLUS
CN 5H-Dibenz[b,f]azepine, 5-[[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]acetyl]-10,11-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 09 Dec 2005
GI



I

AB N-cyanopyrrolidinylcarbonylmethyl amino acid amides such as nonracemic N-cyanopyrrolidinylcarbonylmethyl aminomethylbutanoylisoquinoline I are prepared as dipeptidyl peptidase IV (DPP-IV) inhibitors selective for DPP-IV over the related enzymes DPP-8 and DPP-II for use as potential antidiabetic drugs; the in vitro and in vivo activity of I is determined Boc-protected amino acids are coupled to amines; amine deprotection and alkylation with 1-(bromoacetyl)-(2S)-pyrrolidinecarbonitrile provides the title compds. The DPP-IV-inhibiting structure-activity relationship for a variety of N-substituted aminoacetylpyrrolidinecarbonitriles is determined I suppresses blood glucose elevation after an oral glucose challenge in Wistar rats and also inhibits plasma DPP-IV activity for up to 4 h in BALB/c mice; the in vitro and in vivo activities of I are comparable to those of the antidiabetic agent NVP-LAF237.

ACCESSION NUMBER: 2005:1288271 HCAPLUS
DOCUMENT NUMBER: 144:184000
TITLE: 2-[3-[2-[(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]- 1,2,3,4-tetrahydroisoquinoline: A Potent, Selective, and Orally Bioavailable Dipeptide-Derived Inhibitor of Dipeptidyl Peptidase IV
AUTHOR(S): Tsu, Hsu; Chen, Xin; Chen, Chiung-Tong; Lee, Shiow-Ju; Chang, Chung-Nien; Kao, Kuo-His; Coumar, Mohane Selvaraj; Yeh, Yen-Ting; Chien, Chia-Hui; Wang, Hsin-Sheng; Lin, Ke-Ta; Chang, Ying-Ying; Wu, Ssu-Hui; Chen, Yuan-Shou; Lu, I-Lin; Wu, Su-Ying; Tsai, Ting-Yueh; Chen, Wei-Cheng; Hsieh, Hsing-Pang; Chao, Yu-Sheng; Jiaang, Weir-Torn
CORPORATE SOURCE: Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Taiwan
SOURCE: Journal of Medicinal Chemistry (2006), 49(1), 373-380
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:184000
IT 739366-79-1P 739366-97-3P 739367-07-8P 739367-71-6P 874942-38-8P 874942-39-9P 874942-40-2P 874942-41-3P 874942-42-4P

L4 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of cyanopyrrolidinylcarbonylmethyl-substituted amino acid amides as selective inhibitors of dipeptidyl peptidase IV for potential use as antidiabetic agents)
RN 739366-79-1 HCAPLUS
CN 1H-Isoindole, 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-3-methyl-1-oxobutyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 739366-97-3 HCAPLUS
CN Isoquinoline, 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-3-methyl-1-oxobutyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 739367-07-8 HCAPLUS
CN 1H-Isoindole, 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-1-oxopropyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 739367-71-6 HCAPLUS
CN Isoquinoline, 2-[[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]acetyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 874942-38-8 HCAPLUS
CN Isoquinoline, 2-[4-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-1-oxobutyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 874942-39-9 HCAPLUS
CN Isoquinoline, 2-[(3S)-3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-1-oxobutyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 874942-40-2 HCAPLUS
CN Isoquinoline, 2-[(3R)-3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-4-methyl-1-oxopentyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 874942-41-3 HCAPLUS
CN Isoquinoline, 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-3-methyl-1-oxobutyl]-6-fluoro-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 874942-42-4 HCAPLUS
CN Isoquinoline, 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-3-methyl-1-oxobutyl]-6,8-difluoro-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 22 Sep 2005
GI



I



II

AB Title compds. I [R1 = H or CN; R2-6 independently = H, halo, nitro, etc.; m = 0-5; n and p independently = 0-4; W = O, S, NR7, etc.; R7 = H, halo, alkyl, etc.; X = O, S or CR8(NR9R10); R8-10 independently = H, alkyl or aryl; Y = S, SO, CS, etc.; Z = NR11R12; R11 and R12 independently = H, alkoxyalkyl, haloalkyl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of dipeptidyl peptidase IV (DPP-IV). Thus, e.g., II was prepared by DCC coupling of tert-butoxycarbonyl-L-glutamic acid 5-benzyl ester with pyrrolidine-2-carbonitrile hydrochloride followed by deprotection/coupling/deprotection sequence using 1,2,3,4-tetrahydroisoquinoline in the DCC coupling step. The inhibitory activity of I towards DPP-IV was evaluated using chromogenic enzyme assays and it was found that selected compds. of the invention showed inhibitory activities (no data). I as inhibitors of DPP-IV should prove useful in the treatment of type II diabetes. Pharmaceutical compns. comprising I are disclosed.

ACCESSION NUMBER: 2005:1021623 HCAPLUS
DOCUMENT NUMBER: 143:326200
TITLE: Preparation of pyrrolidine derivatives as inhibitors of dipeptidyl peptidase IV (DPP-IV)
INVENTOR(S): Jiaang, Weir-Tom; Chen, Xin; Wu, Su-Ying; Hsieh, Hsing-Pang; Chao, Yu-Sheng
PATENT ASSIGNEE(S): National Health Research Institutes, Peop. Rep. China
SOURCE: PCT Int. Appl., 42 pp.

L4 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005087235	A1	20050922	WO 2005-US7839	20050309
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005221678	A1	20050922	AU 2005-221678	20050309
CA 2559611	A1	20050922	CA 2005-2559611	20050309
EP 1729774	A1	20061213	EP 2005-725171	20050309
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1942186	A	20070404	CN 2005-80009891	20050309
KR 2007038951	A	20070411	KR 2006-720967	20061009

PRIORITY APPLN. INFO.:			
		US 2004-551419P	P 20040309
		US 2004-617684P	P 20041012
		WO 2005-US7839	W 20050309

OTHER SOURCE(S): MARPAT 143:326200
IT 739367-08-9
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of comparative compound for pyrrolidine derivs. as inhibitors of dipeptidyl peptidase IV)
RN 739367-08-9 HCAPLUS
CN Isoquinoline, 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 864920-96-7P 864921-10-8P 864921-12-0P
864921-13-1P 864921-14-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

L4 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(Uses)
(prepn. of pyrrolidine derivs. as inhibitors of dipeptidyl peptidase IV)

RN 864920-96-7 HCAPLUS
CN 1-Isoquinolineethanol, 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864921-10-8 HCAPLUS
CN Isoquinoline, 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-1-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864921-12-0 HCAPLUS
CN Isoquinoline, 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-1-oxopropyl]-7-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 864921-13-1 HCAPLUS
CN 3-Isoquinolinemethanol, 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 864921-14-2 HCAPLUS
CN Isoquinoline, 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-1-oxopropyl]-1-(1,1-dimethylethyl)-7-fluoro-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 12 Aug 2004
GI



AB The title compds. I (wherein R1 and R2 = independently H, (un)substituted alkyl, CO2H, etc.; R3 = H or (un)substituted aryl; R4 = H or CN; D = CONR6, CO, or NR6CO; R6 = H or (un)substituted alkyl; E = CH2, CH2CH2, CH2CH2CH2, CH2OCH2, or SCH2; n = 0-3; A = (un)substituted bicyclo(hetero)cyclyl] or pharmaceutically acceptable salts thereof are prepared as dipeptidyl peptidase (DPP) IV inhibitors. For example, the compound II•HCl was prepared in a multi-step synthesis. I inhibited DPP IV with IC50 of 0.002 to 0.094 μM.

ACCESSION NUMBER: 2004:648505 HCAPLUS
DOCUMENT NUMBER: 141:190794
TITLE: Preparation of arylcarboxamides as dipeptidyl peptidase IV inhibitors
INVENTOR(S): Kakigami, Takuji; Oka, Mitsuru; Katoh, Noriyasu; Yoshida, Masahiro; Shirai, Masahiro; Murase, Toru; Sakairi, Masao; Yamamoto, Takayo; Takeuchi, Mitsuaki; Hayashi, Yuji; Takeda, Motohiro; Makino, Mitsuhiro
PATENT ASSIGNEE(S): Sanwa Kagaku Kenkyusho Co., Ltd., Japan
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004067509	A1	20040812	WO 2004-JP886	20040130
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
AU 2004207731	A1	20040812	AU 2004-207731	20040130
CA 2514191	A1	20040812	CA 2004-2514191	20040130
EP 1595866	A1	20051116	EP 2004-706796	20040130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1745063	A	20060308	CN 2004-80003342	20040130
US 2006229286	A1	20061012	US 2006-541108	20060201
PRIORITY APPLN. INFO.:			JP 2003-23077 A	20030131

L4 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
WO 2004-JP886 A 20040130

OTHER SOURCE(S): MARPAT 141:190794
IT 739366-79-1P 739366-80-4P 739366-81-5P
739366-82-6P 739366-83-7P 739366-84-8P
739366-85-9P 739366-86-0P 739366-87-1P
739366-88-2P 739366-89-3P 739366-90-6P
739366-91-7P 739366-92-8P 739366-93-9P
739366-94-0P 739366-95-1P 739366-96-2P
739366-97-3P 739366-98-4P 739366-99-5P
739367-00-1P 739367-07-8P 739367-08-9P
739367-09-0P 739367-11-4P 739367-59-0P
739367-60-3P 739367-61-4P 739367-65-8P
739367-66-9P 739367-67-0P 739367-71-6P
739367-72-7P 739367-73-8P 739367-77-2P
739367-78-3P 739367-79-4P 739368-27-5P
739368-29-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of arylcarboxamides as dipeptidyl peptidase IV
inhibitors)

RN 739366-79-1 HCAPLUS
CN 1H-Isoindole, 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-3-methyl-1-oxobutyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 739366-80-4 HCAPLUS
CN 1H-Isoindole, 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-3-methyl-1-oxobutyl]-2,3-dihydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 739366-81-5 HCAPLUS
CN 1H-Isoindole, 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-3-methyl-1-oxobutyl]-5-fluoro-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 739366-82-6 HCAPLUS
CN 1H-Isoindole, 5-bromo-2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-3-methyl-1-oxobutyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 739366-83-7 HCAPLUS
CN 1H-Isoindole, 5-chloro-2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-3-methyl-1-oxobutyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 739366-84-8 HCAPLUS
CN 1H-Isoindole, 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-3-methyl-1-oxobutyl]-5-(1,1-dimethylethyl)-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 739366-89-3 HCAPLUS
CN 1H-Isoindole-5-methanol, 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-3-methyl-1-oxobutyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 739366-90-6 HCAPLUS
CN 1H-Isoindole, 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-3-methyl-1-oxobutyl]-2,3-dihydro-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 739366-91-7 HCAPLUS
CN 1H-Isoindole, 4,5,6,7-tetrachloro-2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-3-methyl-1-oxobutyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 739366-85-9 HCAPLUS
CN 1H-Isoindole, 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-3-methyl-1-oxobutyl]-4-fluoro-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 739366-86-0 HCAPLUS
CN 1H-Isoindole, 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-3-methyl-1-oxobutyl]-2,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 739366-87-1 HCAPLUS
CN 1H-Isoindole, 4,7-dichloro-2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-3-methyl-1-oxobutyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 739366-88-2 HCAPLUS
CN 1H-Isoindol-4-ol, 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-3-methyl-1-oxobutyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 739366-92-8 HCAPLUS
CN 1H-Isoindole, 5,6-dichloro-2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-3-methyl-1-oxobutyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 739366-93-9 HCAPLUS
CN 1H-Isoindol-4-ol, 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-3-methyl-1-oxobutyl]-2,3-dihydro-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 739366-94-0 HCAPLUS
CN 1H-Isoindole, 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-3-methyl-1-oxobutyl]-2,3-dihydro-4-methoxy-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 739366-95-1 HCAPLUS
CN 1H-Isoindole, 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-3-methyl-1-oxobutyl]-2,3-dihydro-5-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 739366-96-2 HCAPLUS
CN 1H-Isoindole, 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-3-methyl-1-oxobutyl]-2,3-dihydro-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 739366-97-3 HCAPLUS
CN Isoquinoline, 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-3-methyl-1-oxobutyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 739366-98-4 HCAPLUS
CN 1H-Isoindole, 2-[2-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-2-methyl-1-oxopropyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 739367-08-9 HCAPLUS
CN Isoquinoline, 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 739367-09-0 HCAPLUS
CN 1H-Isoindole, 2-[4-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-1-oxobutyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 739367-11-4 HCAPLUS
CN 1H-Indole, 1-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 739367-59-0 HCAPLUS
CN 1H-Isoindole, 2-[[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]acetyl]-2,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 739366-99-5 HCAPLUS
CN 1H-2-Benzazepine, 2-[2-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-2-methyl-1-oxopropyl]-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 739367-00-1 HCAPLUS
CN 1H-Isoindole, 2-[4-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-4-methyl-1-oxopentyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 739367-07-8 HCAPLUS
CN 1H-Isoindole, 2-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-1-oxopropyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 739367-60-3 HCAPLUS
CN 1H-Isoindole, 2,3-dihydro-2-[[[2-oxo-2-(3-thiazolidinyl)ethyl]amino]acetyl]- (9CI) (CA INDEX NAME)



RN 739367-61-4 HCAPLUS
CN 1H-Isoindole, 2,3-dihydro-2-[[[2-oxo-2-(1-pyrrolidinyl)ethyl]amino]acetyl]- (9CI) (CA INDEX NAME)



RN 739367-65-8 HCAPLUS
CN 1H-Indole, 1-[[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]acetyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 739367-66-9 HCAPLUS
CN 1H-Indole, 2,3-dihydro-1-[[[2-oxo-2-(3-thiazolidinyl)ethyl]amino]acetyl]-

L4 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(9CI) (CA INDEX NAME)



RN 739367-67-0 HCAPLUS
CN 1H-Indole, 2,3-dihydro-1-[[[2-oxo-2-(1-pyrrolidinyl)ethyl]amino]acetyl]- (9CI) (CA INDEX NAME)



RN 739367-71-6 HCAPLUS
CN Isoquinoline, 2-[[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]acetyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 739367-72-7 HCAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-2-[[[2-oxo-2-(3-thiazolidinyl)ethyl]amino]acetyl]- (9CI) (CA INDEX NAME)



RN 739367-73-8 HCAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-2-[[[2-oxo-2-(1-pyrrolidinyl)ethyl]amino]acetyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 739368-27-5 HCAPLUS
CN Quinoline, 1-[[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]acetyl]decahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 739368-29-7 HCAPLUS
CN 1H-Indole, 1-[3-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-1-oxopropyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 739367-77-2 HCAPLUS
CN Quinoline, 1-[[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]acetyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 739367-78-3 HCAPLUS
CN Quinoline, 1,2,3,4-tetrahydro-1-[[[2-oxo-2-(3-thiazolidinyl)ethyl]amino]acetyl]- (9CI) (CA INDEX NAME)



RN 739367-79-4 HCAPLUS
CN Quinoline, 1,2,3,4-tetrahydro-1-[[[2-oxo-2-(1-pyrrolidinyl)ethyl]amino]acetyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN

AB A series of new spiroglumide amido acid derivs. was synthesized and evaluated for their ability to inhibit the binding of cholecystokinin (CCK) to guinea pig brain cortex (CCKB receptors) and peripheral rat pancreatic acini (CCKA receptors), as well as to inhibit in vitro the gastrin-induced Ca2+ increase in rabbit gastric parietal cells. Appropriate chemical manipulations of the structure of spiroglumide (CR 2194), i.e., (R)-4-(3,5-dichlorobenzamido)-5-(8-azaspiro[4.5]decan-8-yl)-5-oxopentanoic acid, led to potent and selective antagonists of CCKB/gastrin receptors. Structure-activity relationships are discussed. Some of these new derivs., as, for example, compound 54 (CR 2622), i.e., (S)-4-[[(R)-4'-[(3,5-dichlorobenzoyl)amino]-5'-(8-azaspiro[4.5]decan-8-yl)-5'-oxo-pentanoyl]amino]-5-(1-naphthylamino)-5-oxopentanoic acid, exhibit activity 70-170 times greater than that of spiroglumide, depending upon the model used (IC50 = 2+10-8 vs. 140+10-8 mol in binding inhibition of [3H]-N-Me-N-Le-UCCK-8 in guinea pig brain cortex and IC50 = 0.7+10-8 vs. 122.3+10-8 mol in inhibition of gastrin-induced Ca2+ mobilization in parietal cells of rabbit, resp.). Computer-assisted conformational anal. studies were carried out to compare the chemical structure of both the agonist (pentagastrin) and the antagonist (54).

ACCESSION NUMBER: 1995:982948 HCAPLUS
DOCUMENT NUMBER: 124:21030
TITLE: Structure-Antigastrin Activity Relationships of New Spiroglumide Amido Acid Derivatives
AUTHOR(S): Makovec, Francesco; Peris, Walter; Frigerio, Sandra; Giovanetti, Roberto; Letari, Ornella; Mennuni, Laura; Revel, Laura
CORPORATE SOURCE: Rotta Research Laboratorium, Milan, 20052, Italy
SOURCE: Journal of Medicinal Chemistry (1996), 39(1), 135-42
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 124:21030

IT 171202-85-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(structure-activity relationships of new spiroglumide amido acid derivs. as antagonists of CCK/gastrin receptors)

RN 171202-85-0 HCAPLUS
CN 1H-Indole-1-pentanoic acid, γ-[[5-(8-azaspiro[4.5]dec-8-yl)-4-[(3,5-dichlorobenzoyl)amino]-1,5-dioxopentyl]amino]-2,3-dihydro-δ-oxo-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L4 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN

ED Entered STN: 12 May 1984

AB RZXZ1CR1(YR2)NR3CHR4CONR5CR6R7Y1R8 [R = aryl, heterocyclic group, Z = bond; R = aryl, heterocyclic group, H, halo, OH, NH2, guanidino, SH, CO2H, CONH2, or their substituted derivs., Z = C1-15 alkylene, C2-15 alkenylene, C3-15 cycloalkylene, C3-15 cycloalkenylene; X = CO, CH(OH), or their substituted derivs.; Z1 = alkylene, alkenylene, alkylidene; R1 = H, alkyl, aralkyl, YR2; Y, Y1 = CO, CH2; R2, R8 = OH, NH2, or their substituted derivs.; R3 = H, alkyl, carbonyl-containing group; R4 = H, (un)substituted alkyl; R5 = H, alkyl, aralkyl; R6 = H, aryl, heterocyclic group, alkyl, aralkyl, hydroxyalkyl, heterocyclic-substituted alkyl; R5R6 = C2-5 alkylene or alkenylene or their oxa, thia, or aza derivs. or their OH- or oxo-substituted derivs.; R7 = H, alkyl, Y1R8; R6R7 = C2-5 alkylene] were prepared as antihypertensives due to their ability to inhibit angiotensin-converting enzyme (no data). Thus, H-Ala-Pro-OCMe3 was treated with trans-PhCOCH:CHCO2CMe3 in CH2Cl2 for 18 h to give PhCOCH2CH(CO2CMe3)-Ala-Pro-OCMe3, which was deblocked by CF3CO2H to give PhCOCH2CH(CO2H)-Ala-Pro-OH·CF3CO2H.

ACCESSION NUMBER: 1984:23015 HCAPLUS
DOCUMENT NUMBER: 100:23015
TITLE: Amide derivatives
INVENTOR(S): Preston, John; Carling, William Robert
PATENT ASSIGNEE(S): Imperial Chemical Industries PLC, UK
SOURCE: Eur. Pat. Appl., 92 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 84941	A1	19830803	EP 1983-300169	19830113
EP 84941	B1	19870311		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AU 8310341	A	19830728	AU 1983-10341	19830113
AU 563149	B2	19870702		
AT 25850	T	19870315	AT 1983-300169	19830113
ZA 8300273	A	19831026	ZA 1983-273	19830114
HU 27395	A2	19831028	HU 1983-163	19830119
HU 189637	B	19860728		
US 4528282	A	19850709	US 1983-459143	19830119
FI 8300186	A	19830723	FI 1983-186	19830120
DK 8300238	A	19830723	DK 1983-238	19830121
NO 8300203	A	19830725	NO 1983-203	19830121
JP 58134075	A	19830810	JP 1983-7516	19830121
ES 525684	A1	19850701	ES 1983-525684	19830916
ES 525685	A1	19850701	ES 1983-525685	19830916

PRIORITY APPLN. INFO.: GB 1982-1832 A 19820122
EP 1983-300169 A 19830113

L4 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

OTHER SOURCE(S): MARPAT 100:23015

IT 88098-19-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deblocking of)

RN 88098-19-5 HCAPLUS

CN L-Proline, 1-[N-[1-[(1,1-dimethylethoxy)carbonyl]-3-(1H-indol-3-yl)-3-oxopropyl]-L-alanyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 88098-20-8P 88098-21-9P 88098-54-8P
88098-75-3P 88098-84-4P 88122-41-2P
88196-62-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 88098-20-8 HCAPLUS

CN L-Proline, 1-[N-[1-carboxy-3-(1H-indol-3-yl)-3-oxopropyl]-L-alanyl]-(9CI)
(CA INDEX NAME)



RN 88098-21-9 HCAPLUS

CN L-Proline, 1-[N-[1-carboxy-3-(1H-indol-3-yl)-3-oxopropyl]-L-alanyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 88098-20-8
CMF C20 H23 N3 O6



CM 2

L4 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CRN 76-05-1
CMF C2 H F3 O2

RN 88098-54-8 HCAPLUS

CN L-Proline, 1-[N-[5-(2-benzofuranyl)-1-carboxy-5-oxopentyl]-L-alanyl]-, (S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 88098-53-7
CMF C22 H26 N2 O7



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 88098-75-3 HCAPLUS

CN L-Proline, 1-[N-[1,1-bis[(1,1-dimethylethoxy)carbonyl]-4-(1H-indol-3-yl)-4-oxobutyl]-L-alanyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 88098-84-4 HCAPLUS
CN L-Proline, 1-[N2-[1-carboxy-3-(1H-indol-3-yl)-3-oxopropyl]-L-lysyl]-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 88122-41-2 HCAPLUS
CN L-Proline, 1-[N-[1-(ethoxycarbonyl)-3-(1H-indol-3-yl)-3-oxopropyl]-L-alanyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 88196-62-7 HCAPLUS
CN L-Proline, 1-[N-[5-(2-benzofuranyl)-1-carboxy-5-oxopentyl]-L-alanyl]-, (R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 1

CRN 88196-61-6
CMF C22 H26 N2 O7



CM 2

CRN 76-05-1
CMF C2 H F3 O2